Earnings

Teva Confirms Plans To Hive Off API Unit As 2024 Guidance Is Pushed Up Again

Teva Confirms Plans To Hive Off API Unit As 2024 Guidance Is Pushed Up Again

 
• By 

A significant divestment in the works, complex generic launches, a mammoth antitrust fine in Europe – Teva’s Q3 was busy and bustling, led by strong, double-digit top-line growth and a further rise in guidance for 2024.

Biocon’s Growth Rides On FDA Site Inspection Outcomes After Muted Q2

Biocon’s Growth Rides On FDA Site Inspection Outcomes After Muted Q2

 

After under-delivering on already muted expectations, Biocon's optimistic future was overshadowed by pending FDA inspection outcomes on two of its facilities.

Biogen Celebrates As EPO Upholds Tecfidera Patent

Biogen Celebrates As EPO Upholds Tecfidera Patent

 
• By 

Biogen has struck another blow against European generic competitors to Tecfidera, after the European Patent Office upheld a dosage patent for the brand that runs until February 2028. Meanwhile, the firm reported flat biosimilars sales in the third quarter of 2024.

Cipla Signals Lanreotide Supply Strain, Eyes First Wave GLP-1 India Entry

Cipla Signals Lanreotide Supply Strain, Eyes First Wave GLP-1 India Entry

 

Lanreotide supply challenges could impact Cipla’s US revenues in the coming quarter, while the firm hopes it can seize emerging opportunities in the GLP-I segment in India, where Novo Nordisk and Eli Lilly are progressing filings for their blockbuster products.


Sandoz Raises Guidance As Biosimilars Continue To Drive Growth

Sandoz Raises Guidance As Biosimilars Continue To Drive Growth

 
• By 

Sandoz has raised its full-year guidance on the back of third-quarter results that saw the firm enjoy growth of more than a tenth, with biosimilars sales up by a whopping 37%.

Strides To Arm GLP-1 Generics Ahead Of LoEs, As Novo Spars Over Semaglutide Capacity

Strides To Arm GLP-1 Generics Ahead Of LoEs, As Novo Spars Over Semaglutide Capacity

 
• By 

Strides is to supply semaglutide and liraglutide to generics companies amid global capacity constraints and drug shortages, ahead of loss of exclusivity. An ability to make drug-device combinations has meant it has contracts for seven of the eight GLP-1 agonists, and counting.

Sun Pharma Seeing Efforts To Speed Up Development For Complex Generics

Sun Pharma Seeing Efforts To Speed Up Development For Complex Generics

 
• By 

While the firm’s mind and money continues to gear towards branded and novel drugs, India’s Sun Pharma still maintains a mammoth global generics business, including in the US where Sun saw a healthy leap in sales during its financial second quarter.

Samsung Bioepis Reports Q3 Sales Growth, Despite ‘Absence Of Milestones’

Samsung Bioepis Reports Q3 Sales Growth, Despite ‘Absence Of Milestones’

 

After a “remarkable performance” in Q2, Samsung Bioepis enjoyed a calm, but still profitable, third quarter.


Aspen Looks To Soar In GLP-1s With Commercial, Manufacturing Arrangement

Aspen Looks To Soar In GLP-1s With Commercial, Manufacturing Arrangement

 
• By 

Pointing to capacity constraints and an ever-increasing global demand, Aspen has trumpeted its prospects in GLP-1s after striking a deal that could have a significant impact for the firm, both commercially and from a manufacturing standpoint.

Henlius Reports Near 10% Revenue Growth In First Half Of 2024

Henlius Reports Near 10% Revenue Growth In First Half Of 2024

 
• By 

Henlius’ results for the first half of 2024 have shown a continued trend in growing sales of its core biological products on the backdrop of the company’s ongoing privatization by parent company Fosun Pharmaceutical.

Adcock’s Annual Revenues Boosted By Higher Prices Amid Operational Challenges

Adcock’s Annual Revenues Boosted By Higher Prices Amid Operational Challenges

 
• By 

South Africa’s Adcock Ingram welcomed 11 new product launches during its most recent financial year, as it battled on multiple fronts to maintain and ratchet up capacity at its local manufacturing facilities.

‘No Disagreements’ With Former CEO As Endo Looks To Rebuild And Grow

‘No Disagreements’ With Former CEO As Endo Looks To Rebuild And Grow

 
• By 

After emerging from bankruptcy and announcing the departure of its CEO, Endo has spoken in optimistic terms of its future prospects, especially its Sterile Injectable operations.


Complex Generics And Biosimilars Drive First-Half Growth For Stada

Complex Generics And Biosimilars Drive First-Half Growth For Stada

 
• By 

Stada delivered solid growth in the first half of 2024, with complex generics launches and an increasingly prominent biosimilars business enabling two of its three operating divisions to report double-digit sales increases. Meanwhile, management also addressed persistent rumors of a possible sale by Stada’s owners.

Glenmark Chief On ‘Big Shift’ In Revenue By Region, Liraglutide India Outlook

Glenmark Chief On ‘Big Shift’ In Revenue By Region, Liraglutide India Outlook

 

Momentum in Europe may see the region’s contribution to Glenmark’s revenues become almost as big as the US business, currently dented by multiple challenges. The firm also outlines how things are poised in India for its biosimilar to Novo Nordisk’s Victoza.

Alvotech Beginning To Take Flight As Product Sales Treble In H1

Alvotech Beginning To Take Flight As Product Sales Treble In H1

 
• By 

Driven by increased orders, Alvotech is bullish on its US adalimumab biosimilar moving into 2025, as it also look forward to the US launch for its Stelara biosimilar early next year.

Sawai’s Missed Revenue Expectations Leave Analysts Lukewarm Despite Broader Optimism

Sawai’s Missed Revenue Expectations Leave Analysts Lukewarm Despite Broader Optimism

 
• By 

After a transformative last fiscal year, Sawai presented its financial first quarter results for its 2025 year, with slight disappointment among analysts due to missed revenue forecasts.


Lucentis And Stelara Biosimilars Drive Formycon’s 2024 Financials

Lucentis And Stelara Biosimilars Drive Formycon’s 2024 Financials

 

Despite reporting lower revenues in the first half of the year, Formycon continues to see value in its biosimilar projects, with a new candidate to be launched in the second half of 2024.

Zydus Q1: Novel Molecule Enters Phase I, Global Biosimilar Strategy To Shift?

Zydus Q1: Novel Molecule Enters Phase I, Global Biosimilar Strategy To Shift?

 
• By 

Zydus has begun Phase I trials for an anti-properdin drug in India while its sitagliptin franchise in US, distinct from Merck’s Januvia and Janumet, looks promising. Meanwhile MD Sharvil Patel says a biosimilars entry in developed markets is possible if certain conditions are met.

Towa’s First Quarter Performance Draws Analyst Optimism

Towa’s First Quarter Performance Draws Analyst Optimism

 
• By 

Following Towa’s reveal of its medium-term business plan earlier this year, the company has shared its financial first quarter results, which were positively received by select analysts.

Biocon Expects US Adalimumab Market To Consolidate, Liraglutide Plans On Course

Biocon Expects US Adalimumab Market To Consolidate, Liraglutide Plans On Course

 

Biocon maintains it doesn’t expect the US to remain an eight to 10 player market for adalimumab biosimilars for long and also outlines expectations for its GLP-1 portfolio, led by liraglutide, seen as a major growth driver in the coming years.